Kenya first country to launch 'Novartis Access', expanding affordable treatment options against chronic diseases

NovartisToday, Novartis announced the launch of Novartis Access in Kenya, the first country to benefit from a portfolio of 15 affordable medicines to treat cardiovascular diseases, diabetes, respiratory illnesses, and breast cancer. The Novartis portfolio is being offered to the Kenyan government, non-governmental organizations and other public-sector healthcare providers for USD 1 per treatment, per month.

"Novartis and Kenya have a relationship of more than 40 years, so I am delighted that Kenyan patients will be the first to benefit from Novartis Access," said Joerg Reinhardt, Chairman of the Board of Novartis. "The successful implementation of the program in Kenya will be essential to guide the expansion of Novartis Access to other countries in the future."

In conjunction with the launch of the access portfolio and to support effective treatment of chronic diseases in Kenya, Novartis will partner with the Kenyan Ministry of Health, the Kenyan Red Cross, the Kenyan Conference of Catholic Bishops (KCCB), the Christian Health Association of Kenya (CHAK), Management Sciences for Health (MSH) and other key stakeholders. These collaborations are intended to support the healthcare system through measures such as reinforcing drug distribution channels and training healthcare workers to diagnose and treat chronic illnesses. Novartis is also collaborating with Boston University in the US to measure the impact on health in Kenya and steer ongoing development of Novartis Access.

"I am excited by the proactive steps being taken by our government and Novartis in the fight against cancer and other chronic diseases," said H.E. Margaret Kenyatta, First Lady of the Republic of Kenya. "Novartis Access complements the advocacy campaign I have been undertaking together with other African First Ladies to expand access to prevention and treatment for people with chronic diseases."

Some 28 million people die from chronic diseases in low- and middle-income countries each year, representing 75% of such deaths globally.[2] In Kenya, NCDs account for 27% of deaths, or almost 100,000 people per year.[3] By 2030, NCDs are expected to contribute to more than 60% of the total national mortality.[4] In July 2015, the Kenyan government launched a new strategy for the prevention, control and management of NCDs.

"The most pressing health problems can only be solved if the public sector, civil society and the private sector work together," said Dr. Abbas Gullet, Secretary General of the Kenya Red Cross. "Novartis is making an important contribution to fighting NCDs, but in order for Novartis Access to make a long-term impact, we need to drive it locally."

The Novartis Access portfolio includes patented and generic Novartis medicines. The products have been selected based on the World Health Organization's Essential Medicines List and are among the most commonly prescribed medicines. Following Kenya, Novartis Access will be launched in Ethiopia and Vietnam. Over the coming years, Novartis plans to roll out Novartis Access to 30 countries, depending on demand. Novartis expects this new approach to be commercially sustainable over the long term, enabling continuous support in those regions.

About Novartis
Novartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, eye care and cost-saving generic pharmaceuticals. Novartis is the only global company with leading positions in these areas. In 2014, the Group achieved net sales of USD 58.0 billion, while R&D throughout the Group amounted to approximately USD 9.9 billion (USD 9.6 billion excluding impairment and amortization charges). Novartis Group companies employ approximately 120,000 full-time-equivalent associates. Novartis products are available in more than 180 countries around the world.

1. World Health Organization, "UN, Kenyan government take broad-based approach to fighting NCDs". www.who.int/nmh/events/2014/kenya-ncd-prevention/en/ (link is external)
2. World Health Organization, "Noncommunicable diseases fact sheet": http://www.who.int/mediacentre/factsheets/fs355/en/ (link is external), Accessed 14 September 2015
3. World Health Organization, "Noncommunicable diseases, Kenya country profile", 2014: http://www.who.int/nmh/countries/ken_en.pdf (link is external), Accessed 3 October 2015
4. NCD Alliance. http://www.ncdalliance.org/node/3499 (link is external), Accessed 5 October 2015.

Most Popular Now

Top 20 breaking World Pharma News of 2017

We are proud to announce the top 20 most popular breaking World Pharma News from 2017. Have a wonderful 2018 new(s) year filled with health, happiness, and spectacular su...

Novartis advances head-to-head superiority trials …

Novartis announced today the initiation of SURPASS, a head-to-head clinical trial of Cosentyx® (secukinumab) versus proposed biosimilar adalimumab** in ankylosing spondyl...

Roche and Ignyta reach definitive merger agreement

Roche (SIX: RO, ROG; OTCQX: RHHBY) and Ignyta, Inc. (NASDAQ: RXDX) today announced they have entered into a definitive merger agreement for Roche to fully acquire Ignyta ...

Antidepressant may help combat the course of multi…

The antidepressant clomipramine may also alleviate symptoms of multiple sclerosis (MS), specifically in its progressive form, i.e. when it occurs without relapses or remi...

Diabetes drug 'significantly reverses memory loss…

A drug developed for diabetes could be used to treat Alzheimer's after scientists found it "significantly reversed memory loss" in mice through a triple method of action...

FDA updates the label of Tasigna to reflect that c…

The U.S. Food and Drug Administration today updated the product label for the cancer drug Tasigna (nilotonib) to include information for providers about how to discontinu...

Zika remains a research and public health challeng…

Since 2016, when Zika was declared by the World Health Organization as a public health emergency of international concern, the virus has become established in more than 8...

Try exercise to improve memory, thinking

For patients with mild cognitive impairment, don't be surprised if your health care provider prescribes exercise rather than medication. A new guideline for medical pract...

Sandoz regulatory submission for proposed biosimil…

Sandoz, a Novartis division and the global leader in biosimilar medicines, announced today that the US Food and Drug Administration (FDA) has accepted its Biologics Licen...

Dirt-dwelling microbe produces potential anti-mela…

A type of soil-dwelling bacterium produces molecules that induce death in melanoma cells, research at Oregon State University shows. The molecule is a secondary metabolit...

Novartis Kisqali® received FDA Breakthrough Therap…

Novartis today announced Kisqali® (ribociclib) received US Food and Drug Administration (FDA) Breakthrough Therapy designation for initial endocrine-based treatment of pr...

FDA approves first treatment for breast cancer wit…

The U.S. Food and Drug Administration today expanded the approved use of Lynparza (olaparib tablets) to include the treatment of patients with certain types of breast can...

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]